Combining Abiraterone, Niraparib, and Prednisone for Prostate Cancer Treatment

This patent describes a new way to treat prostate cancer by combining three specific medications: abiraterone acetate, niraparib, and prednisone.

What it covers

This patent describes a method for treating prostate cancer using a specific combination of three drugs: abiraterone acetate, niraparib, and prednisone. The disclosure covers both giving these drugs separately (free-dose) or together in a single pill (fixed-dose). The goal is to use these medicines in combination to fight prostate cancer. For example, a doctor might prescribe a patient with prostate cancer a daily regimen that includes all three of these medications to work together against the disease.

What it doesn't cover

• —Does not cover treating prostate cancer with only one or two of the specified drugs, rather than the full combination of abiraterone acetate, niraparib, and prednisone.
• —Does not cover using different drug combinations to treat prostate cancer.
• —Does not cover treating other types of cancer, such as breast cancer or ovarian cancer, with this drug combination.
• —Does not cover methods of treating prostate cancer that do not involve the specific combination of abiraterone acetate, niraparib, and prednisone.

The clever bit

The clever bit is identifying that combining abiraterone acetate, which blocks hormone production, with niraparib, which interferes with cancer cell DNA repair, along with prednisone, could create a more powerful and effective treatment strategy for prostate cancer. This specific combination aims to attack the cancer from multiple angles simultaneously.

Why it matters

Prostate cancer is a common and serious disease, and finding more effective treatments is crucial. This patent matters because it proposes a specific combination of known drugs, abiraterone acetate and niraparib, along with prednisone, to potentially improve patient outcomes. Such combinations can target cancer through multiple pathways, which may lead to better results or help patients who have become resistant to single-drug therapies.

Real-world examples

• 1.Abiraterone acetate (marketed as Zytiga)
• 2.Niraparib (marketed as Zejula)
• 3.Prednisone
• 4.Future fixed-dose combination therapies for prostate cancer